Top Markets
#1 Helium Helium +47.22%
#2 Pons Pons +39.28%
#3 TENDIES TENDIES +24.70%
#4 pipedog pipedog +23.35%
#5 Seeker Seeker +21.59%
#6 UnifAI Network UnifAI Network +19.84%
#7 Bounce Bounce +17.09%
#8 Songbird Songbird +11.97%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +10.49%
#10 OSK OSK +10.30%
Coin of the day
Helium Helium
Inställningar
Språk
SVENSKA
Valuta
USD
Tema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Rankning i aktier #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Aktiekurs
$9.50
Senast synkroniserad: 2025-01-08
Marknadsvärde
$819.52M
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
US
Handel Poseida Therapeutics, Inc. (PSTX)

Kategori

Healthcare
Intäkter för Poseida Therapeutics, Inc. (PSTX)
Intäkter i Sep 2024 TTM: $150.86M
Enligt Poseida Therapeutics, Inc. senaste finansiella rapporter är företagets nuvarande intäkter (TTM) $150.86M. År 2022 hade företaget intäkter på $130.36M en ökning jämfört med intäkterna år 2021, som var $31.24K. Intäkter är det totala belopp som ett företag genererar från försäljning av varor eller tjänster. Till skillnad från vinst dras inga kostnader av.
Intäkts­historik för Poseida Therapeutics, Inc. från 2016 till 2026
Intäkter vid slutet av varje år
År Intäkter Ändra
2026 (TTM) $150.86M 133.15%
2023 $64.70M -50.37%
2022 $130.36M 417,217.08%
2021 $31.24K 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 -100.00%
2017 $2.99M -69.44%
2016 $9.77M 0.00%
Intäkter för liknande företag eller konkurrenter
Företag Intäkter Intäktsdifferens Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 8,268.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 3,891.36%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 10,336.52%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 1,376.89%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH